Time to turn the spotlight on Ireland. Here are the key takeaways from Q2 compiled by Salutem Insights.

 

Highlights:

🏛️ Six HTA assessments, 4 of which are oncology, were completed in Q2 2025.

🤝 One (Birch bark extract, Filsuvez®) considered not value for money and requires price negotiations to secure reimbursement.

💰 Others considered very poor value for money and require further price discounts to secure reimbursement.

 

The stats:

✅ 1 Recommended if cost-effectiveness is improved

❌ 5 Not-recommended until cost-effectiveness be improved

 

📝 Register here to receive the latest and upcoming issues of the complete Access Briefing with HTA insights from 14 countries, compiled by 9 partners of our network 👉 https://forms.office.com/e/Jt8bPmVkdJ